Azitra, Inc. Form 8-K Summary
Business Context and Reporting Period
Azitra, Inc. (NYSE American: AZTR), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on November 24, 2025. The filing details a private placement offering that closed on November 25, 2025, involving the issuance of common stock, pre-funded warrants, and common stock purchase warrants to a single institutional investor.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $1.5 million before deducting expenses.
- Offering Price: $0.32 per share of Common Stock or Pre-Funded Warrant.
- Securities Issued:
- 535,759 shares of Common Stock.
- Pre-Funded Warrants to purchase up to 4,151,741 shares (exercise price $0.0001).
- Common Warrants to purchase up to 4,687,500 shares (exercise price $0.32).
- Placement Agent Fees: 7.0% cash fee of gross proceeds plus warrants to purchase 187,500 shares (4.0% of total shares sold) at 125% of the offering price.
- Use of Proceeds: General corporate purposes.
- Financial Statements: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these operational indicators.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement and a Placement Agency Agreement with Maxim Group LLC. Key contractual terms include:
- Lock-Up Period: A 60-day restriction on issuing additional equity or filing registration statements, subject to exceptions.
- Participation Rights: The Purchaser has the right to participate in up to 25% of any subsequent financing for cash, debt, or a combination thereof until February 26, 2027.
- Beneficial Ownership Limitations: Warrant holders cannot exercise if it results in beneficial ownership exceeding 4.99% of outstanding shares, unless they provide notice to increase the limit to 9.99%.
- Registration Rights: The Company agreed to file a resale registration statement within 20 days and have it declared effective within 60 to 90 days.
Outlook, Risks, and Contingencies
The filing does not contain specific forward-looking guidance, management commentary on future performance, or a discussion of risks beyond standard transactional contingencies. The transaction relies on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D. The Common Warrants are exercisable only upon shareholder approval and expire five years after such approval.
Investor Verification Checklist
- Verify the exact closing date and final settlement of the $1.5 million gross proceeds.
- Confirm the shareholder approval status required for the exercise of Common Warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific representations and warranties.
- Monitor the filing of the Resale Registration Statement within the mandated 20-day window.
- Assess the impact of the 25% participation right on future capital raising efforts through February 2027.